Patisiran
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hereditary Transthyretin-mediated (ATTRv) Amyloidosis
Conditions
Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy
Trial Timeline
Dec 18, 2019 → May 24, 2022
NCT ID
NCT04201418About Patisiran
Patisiran is a pre-clinical stage product being developed by Alnylam Pharmaceuticals for Hereditary Transthyretin-mediated (ATTRv) Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04201418. Target conditions include Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05505838 | Pre-clinical | Completed |
| NCT05023889 | Phase 1 | Active |
| NCT04201418 | Pre-clinical | Completed |
| NCT03862807 | Phase 3 | Completed |
| NCT02510261 | Phase 3 | Completed |
| NCT01617967 | Phase 2 | Completed |
Competing Products
20 competing products in Hereditary Transthyretin-mediated (ATTRv) Amyloidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KVD900 | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 1 | 28 |
| KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 18 |
| KVD900 + Placebo to KVD900 | KalVista Pharmaceuticals | Phase 1 | 28 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 18 |
| Placebo + KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet | KalVista Pharmaceuticals | Phase 1 | 28 |
| KVD900 150 mg + KVD900 300 mg + KVD900 600 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD900 600 mg + Drug: KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| Deferasirox FCT | Novartis | Phase 2 | 52 |
| Canakinumab + Placebo | Novartis | Phase 3 | 77 |
| Ilaris | Novartis | Pre-clinical | 23 |
| Standard of Care for Haemophilia A | Roche | Pre-clinical | 23 |
| Emicizumab | Roche | Phase 3 | 77 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Pre-clinical | 22 |
| Nitisinone | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| Nitisinone | Swedish Orphan Biovitrum | Phase 1 | 32 |